Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.

Grzegorz S NowakowskiDok Hyun YoonAnthea C Peters Patrizia Mondello Erel JoffeIsabelle FleuryRichard GreilMatthew KuReinhard MarksKibum KimPier Luigi ZinzaniJudith TrotmanDan HuangEva E WaltlMark WinderlichNuwan C KurukulasuriyaSumeet AmbarkhaneGeorg HessGilles Andre Salles

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

RE-MIND2, a retrospective observational study, met its primary endpoint, demonstrating prolonged OS with tafasitamab plus lenalidomide versus BR and R-GemOx. See related commentary by Cherng and Westin, p. 3908.

Keyphrases

multiple myeloma
diffuse large b cell lymphoma
stem cell transplantation
newly diagnosed
cross sectional
acute lymphoblastic leukemia
acute myeloid leukemia
tyrosine kinase
low dose
hodgkin lymphoma
drug induced